Travere Therapeutics receives notice of allowance from USPTO
[출처/시간] Briefing.com - 4:59 PM ET, 05/27/2026 Co announces that the US Patent and Trademark Office issued a Notice of Allowance for US Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan
[출처/시간] Briefing.com - 4:59 PM ET, 05/27/2026
Co announces that the US Patent and Trademark Office issued a Notice of Allowance for US Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037. The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Co expects to submit the issued patent for listing in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the "Orange Book") promptly following grant.
당신의 반응은 무엇인가요?
좋아요
0
싫어요
0
사랑
0
재미있는
0
화난
0
슬프다
0
와우
0
